Followers | 144 |
Posts | 27605 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
![](https://investorshub.advfn.com/uicon/33650.png?cb=1628859195)
Wednesday, January 24, 2007 8:37:12 AM
The companies will jointly discover and develop drugs through the use of their complementary platforms.
Gali Weinreb 23 Jan 07 18:56
Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN) has signed an agreement with Medarex Inc. (Nasdaq:MEDX) to jointly discover and develop drugs through the use of their complementary platforms. Compugen knows how to discover and model receptors on cells, while Medarex knows how to produce antibodies adapted to these receptors that will become the basis for drugs.
The companies will jointly develop novel monoclonal antibody-based therapeutics for oncology and autoimmune diseases. They plan to share discovery, development and commercialization responsibilities on antibody-based therapeutics resulting from this collaboration, and share revenues generated from the sale of such therapeutic products.
Although it is difficult at this stage to quantify the expected revenue for Compugen from the agreement, it is clear that this is a strategic agreement for the company. Medarex, which has a market cap of $1.7 billion, is the leading developer of antibody-based therapeutics in the world. The company has 36 candidate molecules for drugs at various stages of clinical trials, including six undergoing Phase III trials. Medarex is jointly developing some of these drugs with other companies, including industry leaders Amgen Inc. (Nasdaq:AMGN), Bristol-Myers-Squibb Inc. (NYSE: BMY), Eli Lilly & Co. (NYSE:LLY), and Novartis AG (NYSE: NVS; LSE: NOV; SWX: NOVZ). Other drugs under development are wholly owned by Medarex. The company posted $56 million revenue in 2005 from these activities, and its revenue is expected to rise sharply if and when one of its drugs is approved for marketing.
Compugen president CEO Alex Kotzer said, “Under the agreement, Medarex will bring us ideas for targets that it wants to develop for drugs. We will find the target receptors and model them so that Medarex can develop molecules for therapeutics. Our development teams will soon hold their first joint meeting to decide where to begin.”
Medarex chairman and interim president and CEO Irwin Lerner said, “We are pleased with this opportunity to pair our UltiMAb Human Antibody Development System technology with new disease targets that may be generated by Compugen's target discovery capabilities and to potentially develop novel therapeutics to fight serious and life-threatening conditions."
This is Compugen’s first agreement for drug development. The company has three strategic agreements for diagnostic products development with Johnson & Johnson (NYSE:JNJ) subsidiary Ortho-Clinical Diagnostics, Inc. (OCD), Diagnostic Products Corporation (recently acquired by Siemens AG (NYSE: SI; XETRA: SIE)), and Biosite Inc. (Nasdaq:BSTE). Compugen is also developing by itself a number of molecules that it discovered with its platform. The most advanced molecules include treatments for metastasized cancer, anti-immune diseases, and cardiovascular diseases.
Published by Globes [online], Israel business news - www.globes.co.il - on January 23, 2007
Recent CGEN News
- Compugen to Present at Upcoming Antibody Industrial Symposium • PR Newswire (US) • 06/17/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/30/2024 11:00:12 AM
- Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig • PR Newswire (US) • 05/30/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/20/2024 11:00:07 AM
- Compugen Reports First Quarter 2024 Results • PR Newswire (US) • 05/20/2024 11:00:00 AM
- U.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices Dip • IH Market News • 05/20/2024 10:59:35 AM
- Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential • PR Newswire (US) • 05/16/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2024 11:02:08 AM
- Compugen Appoints David Silberman as Chief Financial Officer • PR Newswire (US) • 05/15/2024 11:00:00 AM
- Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 • PR Newswire (US) • 05/06/2024 11:00:00 AM
- Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 • PR Newswire (US) • 04/25/2024 11:00:00 AM
- Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 • PR Newswire (US) • 04/10/2024 11:00:00 AM
- Compugen to Participate in Two Upcoming Investor Conferences • PR Newswire (US) • 04/03/2024 11:00:00 AM
- Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy • PR Newswire (US) • 03/11/2024 11:00:00 AM
- Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 • PR Newswire (US) • 03/06/2024 12:00:00 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/05/2024 09:06:21 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 12:00:24 PM
- Compugen Reports Fourth Quarter and Full Year 2023 Results • PR Newswire (US) • 03/05/2024 12:00:00 PM
- U.S. Futures Dip, Crude Oil Fluctuates • IH Market News • 03/05/2024 11:05:54 AM
- Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 • PR Newswire (US) • 02/26/2024 12:00:00 PM
- Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 • PR Newswire (US) • 02/20/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/15/2024 12:00:08 PM
- Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer • PR Newswire (US) • 02/15/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 12:10:06 PM
- Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer • PR Newswire (US) • 01/08/2024 12:05:00 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM